[Evaluation of the analytical performances of the Atellica DCA analyzer (Siemens Healthineers) for point of care determination of HbA].

Fiche publication

Date publication

août 2025

Journal

Annales de biologie clinique

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GILLERY Philippe

Tous les auteurs :
Guillard E, Mourlin A, Mendes D, Leroy N, Florent L, Gillery P, Jaisson S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40767877

Résumé

The importance of HbA1c in the therapeutic monitoring of diabetic patients requires the use of robust and efficient assay methods, especially for point-of-care testing. This study evaluates the analytical performances of the Siemens Healthineers Atellica® DCA. After analyzing linearity and precision, the results were compared with those of the DCA Vantage (Siemens) and the Capillarys 3 Tera (Sebia, capillary electrophoresis). The main interferences (triglycerides and bilirubin) and the effect of total hemoglobin concentration were also assessed. The tests showed a good linearity over a range of 4.5 to 14 % HbA1c, and good precision with coefficients of variation ranging from 1.42 to 2.33 %. The correlation with capillary electrophoresis and the Atellica® DCA was excellent (r² = 0.991 and r² = 0.994, respectively). The accuracy of the results, assessed with external quality samples, was also satisfactory. The method is not sensitive to interference of hypertriglyceridemia up to 10 mmol/L or hyperbilirubinemia (up to 432 μmol/L), and provides reliable results even for low concentrations of total hemoglobin (down to 57,5 g/L). The Atellica® DCA also offers improved ergonomics, with a user-friendly touchscreen and can be connected to the laboratory's management software. this analyzer presents analytical performances suitable for use as point-of-care testing analyzer.